fda blenrep - Search News

News

GSK, food and drug administration and FDA Committee

Bloomberg on MSN · 2h

GSK Falls After FDA Advisory Panel Fails to Back Cancer Drug

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

The Wall Street Journal on MSN · 10h

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therapy.

Reuters on MSN · 1h

GSK shares fall after blood cancer drug likely headed for U.S. rejection

GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.

2h

FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage

Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...

1hon MSN

European Shares Rise as Investors Focus on Earnings

(Reuters) -European shares rose on Friday, on course for small weekly gains, as investors focussed on corporate earnings for ...

Fierce Pharma2d

As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

GlobalData on MSN1d

GSK’s Blenrep US comeback hindered by eye safety concerns

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results